The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers

Cancer Research

Volumn 75, Issue 21, 2015, Pages 4538-4547

  Leonard, Brandon ^a,b   McCann, Jennifer L ^a,b   Starrett, Gabriel J ^a,b   Kosyakovsky, Leah ^a,b,c   Luengas, Elizabeth M ^a,b,c   Molan, Amy M ^a,b   Burns, Michael B ^a,b   McDougle, Rebecca M ^a,b,d   Parker, Peter J ^e,f   Brown, William L ^a,b   Harris, Reuben S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BISINDOLYLMALEIMIDE 1; CYCLOHEXAMIDE; DIACYLGLYCEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHORBOLMYRISTIC ACID; PROTEIN INHIBITOR; PROTEIN KINASE C; SOTRASTAURIN; TPCA 1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; NFKB1 PROTEIN, HUMAN; NFKB2 PROTEIN, HUMAN; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOLOL MYRISTATE ACETATE; RELA PROTEIN, HUMAN; RELB PROTEIN, HUMAN;

APOBEC3B GENE; ARTICLE; BLADDER CANCER CELL LINE; BREAST CANCER CELL LINE; CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MUTAGENESIS; ONCOGENE; OVARIAN CANCER CELL LINE; PKC GENE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; METABOLISM; NEOPLASM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CYTIDINE DEAMINASE; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; PAPILLOMAVIRUS INFECTIONS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TRANSCRIPTIONAL ACTIVATION;

EID: 84946605544     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2171-T     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
2. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149:979-93.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-21.
4. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499:214-8.
5. Poon SL, Pang S-T, McPherson JR, Yu W, Huang KK, Guan P, et al. Genomewide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 2013;5:197ra101.
6. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013;494:366-70.
7. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013;45:977-83.
8. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res 2013;73:7222-31.
9. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBECcytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013;45:970-6.
10. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBECmediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 2014;7: 1833-41.
11. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517: 576-82.
12. Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R, et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol Cell 2012;46:424-35.
13. Refsland EW, Harris RS. The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 2013;371:1-27.
14. Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. MBio 2014;5: E02234-14.
15. Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 2015;89: 688-702.
16. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010;38:4274-84.
17. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
18. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012;7:562-78.
19. Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, et al. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J Invest Dermatol 1999; 113:162-9.
20. Rosse C, Linch M, Kermorgant S, Cameron AJM, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol 2010;11:103-12.
21. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-94.
22. Spitaler M, Cantrell DA. Protein kinase C and beyond. Nat Immunol 2004;5:785-90.
23. Mackay HJ, Twelves CJ. Targeting the protein kinase C family: Are we there yet? Nat Rev Cancer 2007;7:554-62.
24. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 2010;17:222-9.
25. Thielen BK, McNevin JP, McElrath MJ, Hunt BVS, Klein KC, Lingappa JR. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 2010;285:27753-66.
26. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, Johannes FJ. Inhibition of protein kinase Cmu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett 1996;392:77-80.
27. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991;266:15771-81.
28. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993;268:9194-7.
29. Evenou J-P, Wagner J, Zenke G, Brinkmann V, Wagner K, Kovarik J, et al. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmacol Exp Ther 2009;330:792-801.
30. Wagner J, Matt von P, Sedrani R, Albert R, Cooke N, Ehrhardt C, et al. Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin- 4-yl]pyrrole-2, 5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009;52:6193-6.
31. Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocularmelanoma harboringGNAQmutations via effectsonthe PKC/Erk1/2 and PKC/NF-kB pathways. Mol Cancer Ther 2012;11:1905-14.
32. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 2014;33:4724-34.
33. Musi E, Ambrosini G, de Stanchina E, Schwartz GK. The phosphoinositide 3-kinase a selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther 2014;13:1044-53.
34. Piperno-Neumann S, Kapiteijn E, Larkin JMG, Carvajal RD, Luke JJ, Seifert H, et al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. JClin Oncol 2014;32:9030.
35. Wagner J, Matt von P, Faller B, Cooke NG, Albert R, Sedrani R, et al. Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis. J Med Chem 2011;54:6028-39.
36. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.
37. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88- dependent signalling network by targeting the ubiquitin system. Biochem J 2013;451:427-37.
38. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl) amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 2005;312:373-81.
39. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, Brennan F, et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NFkappaB dependent. Proc Natl Acad Sci 1998;95:8211-5.
40. Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, et al. TNFalpha gene expression in macrophages: Regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol 2000;164:4277-85.
41. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.
42. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
43. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 2014;346:945-9.
44. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
45. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
46. Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer 2014;5: 405-13.
47. Cescon DW, Haibe-Kains B, Mak TW. APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A 2015; 112:2841-6.